JP2019536457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536457A5 JP2019536457A5 JP2019529204A JP2019529204A JP2019536457A5 JP 2019536457 A5 JP2019536457 A5 JP 2019536457A5 JP 2019529204 A JP2019529204 A JP 2019529204A JP 2019529204 A JP2019529204 A JP 2019529204A JP 2019536457 A5 JP2019536457 A5 JP 2019536457A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- recombinant
- cells
- mouse
- immunodeficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022166015A JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428131P | 2016-11-30 | 2016-11-30 | |
| US62/428,131 | 2016-11-30 | ||
| US201762565783P | 2017-09-29 | 2017-09-29 | |
| US62/565,783 | 2017-09-29 | ||
| PCT/US2017/063948 WO2018102546A1 (en) | 2016-11-30 | 2017-11-30 | Humanized mouse model with improved human innate immune cell development |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166015A Division JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536457A JP2019536457A (ja) | 2019-12-19 |
| JP2019536457A5 true JP2019536457A5 (https=) | 2021-01-21 |
| JP7458185B2 JP7458185B2 (ja) | 2024-03-29 |
Family
ID=60935945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529204A Active JP7458185B2 (ja) | 2016-11-30 | 2017-11-30 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
| JP2022166015A Pending JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022166015A Pending JP2023015064A (ja) | 2016-11-30 | 2022-10-17 | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20190320633A1 (https=) |
| EP (1) | EP3547831B1 (https=) |
| JP (2) | JP7458185B2 (https=) |
| CN (1) | CN110740641A (https=) |
| WO (1) | WO2018102546A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110740641A (zh) * | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| RU2019140867A (ru) | 2017-05-12 | 2021-06-15 | Зе Джексон Лаборатори | Nsg мыши, не имеющие mhc класса i и класса ii |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| US20210355501A1 (en) * | 2018-09-24 | 2021-11-18 | Albert Einstein College Of Medicine | Interleukin-8 for maintenance of human acute myeloid leukemia and myelodysplastic syndrome and uses thereof |
| US20220192166A1 (en) * | 2019-03-28 | 2022-06-23 | Central Institute For Experimental Animals | Immunodeficient rodent |
| WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| CN111705082A (zh) * | 2020-04-14 | 2020-09-25 | 澎立生物医药技术（上海）有限公司 | 具有髓系免疫细胞的人源化免疫系小鼠的构建方法 |
| WO2022011010A1 (en) * | 2020-07-08 | 2022-01-13 | The Jackson Laboratory | Transgenic mouse model expressing human hla-a201 restriction gene |
| KR20230074758A (ko) | 2020-09-24 | 2023-05-31 | 더 잭슨 래보라토리 | 면역 세포 요법을 평가하기 위한 인간화 마우스 모델 |
| WO2022222958A1 (en) * | 2021-04-20 | 2022-10-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| IL313760A (en) * | 2021-12-22 | 2024-08-01 | Jackson Lab | Human mouse models |
| EP4547274A1 (en) | 2022-06-30 | 2025-05-07 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd25-specific antibodies and uses thereof |
| US20260083106A1 (en) * | 2022-09-08 | 2026-03-26 | The Jackson Laboratory | Humanized immunodeficient mouse models |
| EP4608969A1 (en) * | 2022-10-25 | 2025-09-03 | Lapix Therapeutics, Inc. | Immune cell-engrafted non-human animals and non-human animal models |
| WO2025041060A1 (en) * | 2023-08-21 | 2025-02-27 | VeraVerse Co., Ltd. | Patient-derived xenograft model of cancer, preparation method thereof and an apparatus and a method for analyzing drug responsiveness using the same |
| WO2026001958A1 (zh) * | 2024-06-24 | 2026-01-02 | 黄菁 | Aav载体、aav载体的组合、构建aml pdx和mm pdx非人动物的方法及构建免疫系统人源化非人动物的方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015521A1 (en) * | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| ES2463476T3 (es) * | 2004-10-19 | 2014-05-28 | Regeneron Pharmaceuticals, Inc. | Método para generar un ratón homocigótico para una modificación genética |
| SG10202008003VA (en) * | 2011-02-15 | 2020-10-29 | Regeneron Pharma | Humanized m-csf mice |
| FI2892330T3 (fi) * | 2012-09-07 | 2023-03-25 | Univ Yale | Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi |
| MX377561B (es) * | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| ES2613379T3 (es) | 2013-10-15 | 2017-05-24 | Regeneron Pharmaceuticals, Inc. | Animales con IL-15 humanizada |
| US20150282460A1 (en) | 2014-04-04 | 2015-10-08 | Crown Bioscience Inc. (Taicang) | Animal model with human immune system |
| MX2016014995A (es) * | 2014-05-19 | 2017-03-31 | Regeneron Pharma | Animales no humanos geneticamente modificados que expresan eritropoyetina de humano. |
| ES2950399T3 (es) | 2015-04-13 | 2023-10-09 | Regeneron Pharma | Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos |
| JP6654001B2 (ja) | 2015-05-27 | 2020-02-26 | 公益財団法人実験動物中央研究所 | ヒトｉｌ−１５分泌免疫不全マウス |
| HK1255123A1 (zh) * | 2015-06-23 | 2019-08-02 | The Jackson Laboratory | 具有患者衍生异种移植物的非hla匹配的人源化nsg小鼠模型 |
| US20180325085A1 (en) | 2015-10-30 | 2018-11-15 | The Jackson Laboratory | Compositions and methods relating to tumor analysis |
| RU2019115976A (ru) | 2016-10-27 | 2020-11-27 | Зэ Джэксон Лэборэтори | Модель с использованием генетически модифицированной мыши для ксенотрансплантации гепатоцитов человека |
| CN110740641A (zh) * | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| WO2019006472A1 (en) * | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| EP3664603B1 (en) | 2017-08-09 | 2024-01-03 | The Jackson Laboratory | Immunodeficient mice expressing human interleukin 15 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| WO2020092655A1 (en) | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Methods for allogeneic hematopoietic stem cell transplantation |
-
2017
- 2017-11-30 CN CN201780083557.8A patent/CN110740641A/zh active Pending
- 2017-11-30 JP JP2019529204A patent/JP7458185B2/ja active Active
- 2017-11-30 EP EP17825653.3A patent/EP3547831B1/en active Active
- 2017-11-30 WO PCT/US2017/063948 patent/WO2018102546A1/en not_active Ceased
- 2017-11-30 US US16/465,006 patent/US20190320633A1/en not_active Abandoned
-
2022
- 2022-10-17 JP JP2022166015A patent/JP2023015064A/ja active Pending
-
2024
- 2024-06-28 US US18/758,838 patent/US12409237B1/en active Active
-
2025
- 2025-08-15 US US19/301,265 patent/US20260033467A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536457A5 (https=) | ||
| Bruchard et al. | Deciphering the roles of innate lymphoid cells in cancer | |
| Katano et al. | Predominant development of mature and functional human NK cells in a novel human IL-2–producing transgenic NOG mouse | |
| Mian et al. | Advances in human immune system mouse models for studying human hematopoiesis and cancer immunotherapy | |
| Hanazawa et al. | Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice | |
| DuPré et al. | The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci | |
| McCaughtry et al. | Conditional deletion of cytokine receptor chains reveals that IL-7 and IL-15 specify CD8 cytotoxic lineage fate in the thymus | |
| JP2022105531A (ja) | 遺伝学的に修飾された非ヒト動物およびその使用法 | |
| EP3475413B1 (en) | Genetically modified t lymphocytes | |
| JP2012531896A5 (https=) | ||
| Bascuas et al. | Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice | |
| Chou et al. | Immunomodulatory effects of Saccharomyces cerevisiae fermentation product supplementation on immune gene expression and lymphocyte distribution in immune organs in broilers | |
| JP2020520367A5 (https=) | ||
| US20150282460A1 (en) | Animal model with human immune system | |
| Kumari et al. | Humanized mouse models for immuno‐oncology drug discovery | |
| Stacey et al. | IL-10 restricts activation-induced death of NK cells during acute murine cytomegalovirus infection | |
| Volk et al. | Multidimensional analysis integrating human T-cell signatures in lymphatic tissues with sex of humanized mice for prediction of responses after dendritic cell immunization | |
| Li et al. | Thymic selection pathway regulates the effector function of CD4 T cells | |
| Prlic et al. | Dissociating markers of senescence and protective ability in memory T cells | |
| US11725187B2 (en) | Selection of human hematopoetic stem cells using EPCR | |
| KR102581970B1 (ko) | 면역 부전 마우스 | |
| Panjwani et al. | Single-cell profiling aligns CD56bright and cytomegalovirus-induced adaptive natural killer cells to a naïve-memory relationship | |
| WO2017049002A1 (en) | A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system | |
| Mendoza-Valderrey et al. | Next generation immuno-oncology strategies: unleashing NK cells activity | |
| Pisano et al. | Laboratory mice–A driving force in immunopathology and immunotherapy studies of human multiple myeloma |